

1
2 **The Effect of Intensivist Communication in a Simulated Setting**
3 **on Interpretation of Prognosis Among Family Members of**
4 **Patients at High Risk for ICU Admission: A Randomized Trial**

5
6 **Unique Protocol Identification Number: IRB00204036**

7 **National Clinical Trial (NCT) Identified Number: NCT04239209**

8 **Principal Investigator: Alison Turnbull**

9 **Sponsor: Johns Hopkins University**

10 **Grant Title: Gordon and Betty Moore Foundation Early Career Award**

11 **Grant Number: 4626**

12 **Funded by: NHLBI, Gordon and Betty Moore Foundation**

13 **Version Number: v.1.000**

14 **15 January 2020**

15
16
17 **Important**

18 The original protocol for this study was reviewed by the Johns Hopkins IRB-6 and determined
19 on August 8, 2019 to qualify as exempt research under the DHHS regulations (IRB00204036). It
20 is available from the principal investigator upon request.

21
22 This revised and reformatted version of the study protocol was created in January, 2020 at the
23 request of the reviewing journal.

Table of Contents

26

27 Statement of Compliance 4

28 Investigator's Signature 4

29 1 Protocol Summary 5

30 1.1 Synopsis 5

31 1.2 Schema..... 7

32 1.3 Schedule of Activities 8

33 2 Introduction 9

34 2.1 Study Rationale 9

35 2.2 Background 10

36 2.3 Risk/Benefit Assessment 10

37 2.3.1 Known Potential Risks 10

38 2.3.2 Known Potential Benefits..... 10

39 2.3.3 Assessment of Potential Risks and Benefits 10

40 3 Objectives and Endpoints 11

41 4 Study Design 12

42 4.1 Overall Design 12

43 4.2 Scientific Rationale for Study Design 12

44 4.3 Justification for Intervention..... 12

45 4.4 End-of-Study Definition..... 13

46 5 Study Population 14

47 5.1 Inclusion Criteria 14

48 5.2 Exclusion Criteria..... 14

49 5.3 Lifestyle Considerations 14

50 5.4 Screen Failures 14

51 5.5 Strategies for Recruitment and Retention 14

52 6 Study Intervention(s) or Experimental Manipulation(s) 15

53 6.1 Study Intervention(s) or Experimental Manipulation(s) Administration 15

54 6.1.1 Study Intervention or Experimental Manipulation Description 15

55 6.1.2 Administration and/or Dosing..... 15

56 6.2 Fidelity..... 15

57 6.2.1 INTERVENTIONIST TRAINING AND TRACKING..... 15

58 6.3 Measures to Minimize Bias: Randomization and Blinding 15

59 6.4 Study Intervention/Experimental Manipulation Adherence 15

60 6.5 Concomitant Therapy 15

61 6.5.1 Rescue Therapy 16

62 7 Study Intervention/Experimental Manipulation Discontinuation and Participant Discontinuation/Withdrawal ... 17

63 7.1 Discontinuation of Study Intervention/Experimental Manipulation 17

64 7.2 Participant Discontinuation/Withdrawal from the Study 17

65 7.3 Lost to Follow-Up 17

66 8 Study Assessments and Procedures..... 18

67 8.1 Endpoint and Other Non-Safety Assessments 18

68 8.2 Safety Assessments 19

69 8.3 Adverse Events and Serious Adverse Events 19

70 8.4 Unanticipated Problems 19

71 8.4.1Definition of Unanticipated Problems 19

72 8.4.2Unanticipated Problems Reporting..... 20

73 8.4.3 Reporting Unanticipated Problems to Participants 20
74 9 Statistical Considerations 21
75 9.1 Statistical Hypotheses 21
76 9.2 Sample Size Determination 21
77 9.3 Populations for Analyses 21
78 9.4 Statistical Analyses 21
79 9.4.1 General Approach 21
80 9.4.2 Analysis of the Primary Endpoint(s) 22
81 9.4.3 Analysis of the Secondary Endpoint(s) 22
82 9.4.4 Safety Analyses 22
83 9.4.5 Baseline Descriptive Statistics 22
84 9.4.6 Planned Interim Analyses 22
85 9.4.7 Sub-Group Analyses 22
86 9.4.8 Tabulation of Individual Participant Data 22
87 9.4.9 Exploratory Analyses 22
88 10 Supporting Documentation and Operational Considerations 24
89 10.1 Regulatory, Ethical, and Study Oversight Considerations 24
90 10.1.2 Study Discontinuation and Closure 24
91 10.1.3 Confidentiality and privacy 24
92 10.1.4 Future Use of Stored Specimens and Data 25
93 10.1.6 Safety Oversight 25
94 10.1.7 Clinical Monitoring 25
95 10.1.8 Quality Assurance and Quality Control 25
96 10.1.9 Data Handling and Record Keeping 25
97 10.1.10 Protocol Deviations 26
98 10.1.11 Publication and Data Sharing Policy 26
99 10.1.12 Conflict of Interest Policy 26
100 10.2 Additional Considerations 26
101 10.3 Abbreviations and Special Terms 26
102 10.4 Protocol Amendment History 26
103 11 References 28
104 References 28
105
106
107

108 **STATEMENT OF COMPLIANCE**

109 All personnel involved in the conduct of this study have completed Human Subjects Protection and ICH GCP
110 Training.

111
112 The protocol, informed consent form(s), and all participant materials will be submitted to the IRB for review and
113 approval. Approval of both the protocol and the consent form(s) must be obtained before any participant is
114 consented. Any amendment to the protocol will require review and approval by the IRB before the changes are
115 implemented to the study. All changes to the consent form(s) will be IRB approved.

116 **INVESTIGATOR'S SIGNATURE**

117 **Principal Investigator or Clinical Site Investigator:**

Signed:  Date: 1/21/2020
Name*: Alison E. Turnbull
Title*: Assistant Professor

118
119
120 **Investigator Contact Information:**

Affiliation*: Johns Hopkins University
Address: 1830 E. Monument St
Telephone: 410-955-2190
Email: turnbull@jhmi.edu

1 PROTOCOL SUMMARY


1.1 SYNOPSIS

| | | |
|--|---|---|
| Title: | The Effect of Intensivist Communication on Prognosis Interpretation by Family Members of Patients at High Risk for Intensive Care Unit Admission: A Randomized Trial | |
| Grant Number: | 4626 | |
| Study Description: | This study evaluates the effect of physician communication styles on the interpretation of prognosis by family members of chronically-ill patients. Participants were randomized to view one of four videos how depicting different physicians disclose prognosis when they expect an ICU patient to die. | |
| Objectives*: | Primary Objective: | Quantify participant perceptions of the intensivist's prognostic estimate. |
| | Secondary Objectives: | 1) Quantify participant prognostic estimates. 2) Quantify participant differences in belief about prognosis. 3) Describe participant confidence that they understood the intensivist's belief about prognosis. 4) Describe participant confidence in their own prognostic estimate. |
| Endpoints*: | Primary Endpoint: | Participant response to the question "If you had to guess, what do you think the doctor thinks is the chance that your loved one will survive this hospitalization?" answered on a 0-100% probability scale. |
| | Secondary Endpoints: | 1) Participant response to the question "What do you think are the chances that your loved one will survive this hospitalization?" answered on a 0-100% probability scale. 2) The difference between the participant's prognostic estimate and the participant's perception of the intensivist's prognostic estimate. 3) Participant confidence in their ability to interpret the doctor's prognostic estimate of survival (primary outcome) using a 5-item Likert scale. 4) Participant confidence in their own estimate of their loved one's chances of survival to discharge using a 5-item Likert scale. |
| Study Population: | People age ≥ 18 years who are a spouse/partner, sibling, or adult child of a patient with Chronic Obstructive Pulmonary Disease (COPD) on home oxygen. | |
| Phase* or Stage: | n/a | |
| Description of Sites/Facilities Enrolling Participants: | Web-based trial. | |

Description of Study One of four videos depicting different intensivist communication styles.
Intervention/Experimental Manipulation:
Study Duration*: 3 weeks
Participant Duration: 20 minutes on average

125
126

1.2 SCHEMA



129
130

131

1.3 SCHEDULE OF ACTIVITIES

132
133

This is an online-only randomized trial. When the participant consents to participate the trial begins. Once all study questions are answered the participant's involvement in the study ceases.

134
135

2 INTRODUCTION

2.1 STUDY RATIONALE

The majority of Americans surveyed >65 years old would prefer to forego mechanical ventilation and other life support therapies and, instead, die at home with supportive care^{1,2} and most patients do not change their end of life preferences over time or after changes in health status.³ **However, Intensive Care Unit (ICU) use during the last month of life has increased for >15 years to nearly 30%.**^{4,5,6} Additionally, among hospitalized patients with advanced dementia and severe functional impairment, **mechanical ventilation use doubled between 2000-2013 without a significant improvement in survival.**⁷ Compared to other developed countries, the United States has a much higher use of intensive care services at the end of life.^{8,9} Death in an ICU amongst patients with cancer has been associated with more physical and emotional distress and worse quality of life at the end of life, in addition to increased risk of psychiatric illness in bereaved caregivers compared to those who die at home with hospice.¹⁰ This discordance between preferred and actual site of death, led to the following recommendation by the American Board of Internal Medicine Foundation's *Choosing Wisely* campaign: **"Don't continue life support for patients at high risk for death or severely impaired functional recovery without offering patients and their families the alternative of care focused entirely on comfort."**¹¹ This study will help clarify how to clearly convey the prognosis of ICU patients, which is essential to do before offering care focused on comfort.

Studying Communication in the ICU: Because critical illness prevents many patients from communicating with the medical team, family surrogates frequently act as decision-makers for most ICU patients.¹² Effective communication about prognosis with these surrogates is essential to ensuring they make informed decisions about their loved one's care.¹³ Indeed, the Institute of Medicine's report *Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life* recommends **improving clinicians' ability to talk effectively to patients about dying.**¹⁴ When the option of speaking directly to the patient is absent, such as in the ICU, this recommendation also applies to patient surrogates. Previous trials have examined different methods for communicating prognosis to ICU surrogates,^{15 16} but **substantial intensivist-surrogate discordance about prognosis remains**^{15 17 18} even when surrogates rate the quality of physician communication highly.¹⁹ Recent research suggests intensivist-surrogate discordance about prognosis is a result of both surrogate misunderstanding and differences between physician and surrogate belief systems.^{17 20} While surrogate belief systems are largely immutable, **misunderstandings due to communication failures are a correctable target for intervention.**

Limitations in Current Research Methods: Most research on communicating with ICU surrogates has studied surrogates of current ICU patients. Anxiety, depression, sleep deprivation, anticipatory grief, and post-traumatic stress disorder are common in this population,^{21 22 23 24} and may affect decision making.^{21 22 25} Surveys aimed at surrogates of current ICU patients may be biased towards respondents who are white,²⁶ visit the hospital more frequently,²⁷ and are of a higher socioeconomic status.^{26 28} To address these problems, we will study close family members (spouses, siblings, and adult children) of outpatients who are ill enough that ICU admission in the near future is likely, thus examining a population of potential surrogates who are not acutely stressed about a loved one's day-to-day survival in the ICU. Specifically, we will study family members of adults with Chronic Obstructive Pulmonary Disease (COPD) requiring home oxygen, as these family members are likely to become patient surrogates in the near future.^{29 30}

2.2 BACKGROUND

Foundational studies leading to this current protocol included a vignette-based online randomized trial which demonstrated that requiring intensivists to record patients' expected functional prognosis substantially increased their intention to discuss withdrawing life support.³¹ A subsequent double-blind randomized controlled trial was then performed to test the effect of requiring intensivists to document short-term and long-term functional prognosis on their communication behaviors in a family meeting conducted with an actor in a well-controlled, high-fidelity, hospital-based simulation center (ClinicalTrials.gov NCT02721810).³² A total of 116 U.S. intensivists were recruited to the Johns Hopkins Hospital Simulation Center where they reviewed paper-based medical records of a hypothetical patient scenario, developed so that in-hospital death was highly probable but not certain. Physicians in both the control and intervention groups were then asked a series of questions about their management plan; intensivists randomized to the intervention group also answered 3 additional questions about the hypothetical patient's prognosis. One question, which we will use the responses to in our study, was "Do you expect this patient to survive to hospital discharge?"^{15 17} All intensivists then participated in a standardized, video- and audio-recorded, simulated family meeting, using specially trained and paid actors portraying the patient's daughter. Two blinded ICU-physician reviewers then analyzed each transcribed recording. Study participant behaviors and language during the simulations then underwent a qualitative analysis and categorization into different communication patterns by two blinded physician reviewers. The analysis centered on the response of the intensivist to a portion of the simulation where the actor was told to signpost a specific desire to know prognosis by asking the question "*What do you think is most likely to happen?*"³³ From this analysis, four videos were selected to demonstrate archetypal physician communication patterns - direct communication, indirect focusing on physiology, indirect focusing on other patients, and redirection. Each video came from an intensivist who thought that the hypothetical patient would not survive the hospital stay, and each intensivist answered that they had conveyed the prognosis for a risk of death to the family member in the simulation.

2.3 RISK/BENEFIT ASSESSMENT

2.3.1 KNOWN POTENTIAL RISKS

There is a small risk of loss of confidentiality.

2.3.2 KNOWN POTENTIAL BENEFITS

Participants will not individually benefit from this research. The proposed research has the potential to support guidelines and interventions to improve prognosis communication in the intensive care unit.

2.3.3 ASSESSMENT OF POTENTIAL RISKS AND BENEFITS

The risks involved with this study are minimal and benefits to ICU care in general could be large.

211 **3 OBJECTIVES AND ENDPOINTS**

212

| OBJECTIVES | ENDPOINTS | JUSTIFICATION FOR ENDPOINTS | PUTATIVE MECHANISMS OF ACTION |
|--|--|---|---|
| Primary | | | |
| Quantify participant perceptions of the intensivist's prognostic estimate | Participant response to the question "If you had to guess, what do you think the doctor thinks is the chance that your loved one will survive this hospitalization?" answered on a 0-100% probability scale. | This exact question has been used in a prior landmark study of of prognosis communication with ICU proxies. ¹⁷ | Health literacy, health numeracy, physician communication skills and word choice. |
| Secondary | | | |
| Quantify participant prognostic estimates. | Participant response to the question "What do you think are the chances that your loved one will survive this hospitalization?" answered on a 0-100% probability scale. | This exact question has been used in a prior landmark study of of prognosis communication with ICU proxies. ¹⁷ | Optimism, hope, religious faith, trust in physicians, misunderstanding, health literacy, health numeracy, physician communication skills and word choice. |
| Quantify participant difference in belief about prognosis. | The difference between the participant's prognostic estimate and the participant's perception of the intensivist's prognostic estimate. | This definition was established in a prior landmark study on prognosis communication with ICU proxies. ¹⁷ | Optimism, hope, religious faith, trust in physicians |
| Tertiary/Exploratory | | | |
| Describe participant confidence that they understood the intensivist's belief about prognosis. | Participant confidence in their ability to interpret the doctor's prognostic estimate of survival (primary outcome) using a 5-item Likert scale. | Exploratory outcome. | Prior experience speaking with intensivists. |
| Describe participant confidence in their own prognostic estimate. | Participant confidence in their own estimate of their loved one's chances of survival to discharge using a 5-item Likert scale. | Exploratory outcome. | Prior experience advocating for a critically ill loved one. |

4 STUDY DESIGN

4.1 OVERALL DESIGN

Study Type: Interventional

Primary Purpose: Other

Study Phase: N/A

Interventional Study Model: Parallel Assignment

Participants are randomized in a 1:1:1:1 ratio to view a video depicting one of four different ways intensivists answered a patient surrogate's prognostic question "What do you think is most likely to happen?" during a simulated ICU family meeting.

Number of Arms: 4

Masking: None (Open Label)

Allocation: Randomized

Enrollment: 302 [Actual]

4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN

A randomized trial is the ideal way to study the effect of different intensivist communication styles on surrogate prognosis interpretation. We have designed our trial to be simulation-based in order to avoid the ethical dilemma of randomly subjecting surrogates of current ICU patients to experiencing different communication styles when intensivists deliver prognosis, some of which we hypothesize to be less effective. We have also designed the trial to recruit a sample of people who are not currently acting as surrogates for their family member in an ICU but have a high likely of doing so in the future. This trial design also allows us to control for the many factors which are hypothesized to affect how families interpret statements about prognosis in the ICU.

4.3 JUSTIFICATION FOR INTERVENTION

Previous research has shown that intensivists convey prognosis in many different ways. The interventions, videos depicting different styles of communicating prognosis, were created from verbatim transcripts obtained during a prior simulation trial (see 2.2 Background). A prior qualitative study (see 2.2 Background) then classified the videos into four categories of communication style, which are used in the present trial as an intervention.

245

4.4 END-OF-STUDY DEFINITION

246

Sample size has been accrued and all participants have finished the single online trial session.

247

248

5 STUDY POPULATION

5.1 INCLUSION CRITERIA

Spouse/partner, sibling, or adult child of a patient with Chronic Obstructive Pulmonary Disease (COPD) on home oxygen, and ≥ 18 years old.

5.2 EXCLUSION CRITERIA

Current or previous experience as a nurse, advanced practice provider, or physician

5.3 LIFESTYLE CONSIDERATIONS

N/A

5.4 SCREEN FAILURES

Screen failures will be excluded from the study and partial responses will not be analyzed.

5.5 STRATEGIES FOR RECRUITMENT AND RETENTION

Recruitment will occur via Qualtrics LLC, who will distribute our online trial to their proprietary pre-existing survey panels.

6 STUDY INTERVENTION(S) OR EXPERIMENTAL MANIPULATION(S)

6.1 STUDY INTERVENTION(S) OR EXPERIMENTAL MANIPULATION(S) ADMINISTRATION

6.1.1 STUDY INTERVENTION OR EXPERIMENTAL MANIPULATION DESCRIPTION

The intervention consists of a short (< 1 minute) video of an intensive care physician communicating a hypothetical patient's prognosis directly to the camera. The trial participant will be asked to imagine that their loved one with COPD is in the ICU, that they have asked the doctor the question "What do you think is most likely to happen?" and that the video depicts their doctor's response to that question.

6.1.2 ADMINISTRATION AND/OR DOSING

This is a web-based video hosted on a video streaming website. It is integrated into the Qualtrics online platform.

6.2 FIDELITY

6.2.1 INTERVENTIONIST TRAINING AND TRACKING

N/A

6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING

Randomization occurs via a computer algorithm integrated within the Qualtrics online platform. Participants will be randomized in a 1:1:1:1 ratio to view one of the four study videos.

6.4 STUDY INTERVENTION/EXPERIMENTAL MANIPULATION ADHERENCE

N/A - the study consists of only one online encounter.

6.5 CONCOMITANT THERAPY

299

6.5.1 RESCUE THERAPY

300

N/A

301

302

303 **7 STUDY INTERVENTION/EXPERIMENTAL MANIPULATION DISCONTINUATION AND PARTICIPANT**
304 **DISCONTINUATION/WITHDRAWAL**

305 **7.1 DISCONTINUATION OF STUDY INTERVENTION/EXPERIMENTAL MANIPULATION**

306 N/A

307
308
309 **7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY**

310 Participants may withdraw from answering study questions at any time by closing their web browser.

311
312
313 **7.3 LOST TO FOLLOW-UP**

314 N/A - There is only one study session as part of this online trial.

315
316

8 STUDY ASSESSMENTS AND PROCEDURES

8.1 ENDPOINT AND OTHER NON-SAFETY ASSESSMENTS

The entire trial occurs online. Participants are asked the following questions:

Screening questions:

Have you ever worked as a doctor, nurse, or advanced practice provider (PA, NP, MSN, etc.)? [Yes, No]

How old are you?

Are you the spouse, partner, child, or sibling of someone with any of the following conditions? [renal (kidney) disease requiring regular dialysis, Chronic Obstructive Pulmonary Disease (also called COPD or emphysema, Severe dementia, None of the above]

Is your loved one with Chronic Obstructive Pulmonary Disease (also called COPD or emphysema) deceased? [Yes, No]

Does your loved one with Chronic Obstructive Pulmonary Disease (also called COPD or emphysema) require oxygen at home? [Yes, No]

Has your loved one with COPD ever needed a breathing machine (also known as a ventilator) during a hospital stay? [Yes, No, Unsure/I don't know]

What best describes your relationship to the person with Chronic Obstructive Pulmonary Disease (also called COPD or emphysema) requiring oxygen at home? [Spouse/Partner, Parent/Step-Parent, Sibling, None of the above]

Participants are then given the simulation instructions and instructions for watching the video.

The video then plays.

Study questions are asked immediately after the video is complete:

What do you hope (best case scenario) is the chance that your loved one survives the hospitalization? [answered on a 0-100% scale]

What do you think are the chances that your loved one will survive this hospitalization? [answered on a 0-100% scale]

How confident are you that you understand your loved one's chances for surviving the hospitalization? [answered on a 5-item Likert scale]

If you had to guess, what do you think the doctor thinks is the chance that your loved one will survive this hospitalization? [answered on a 0-100% scale]

How confident are you that you know what the doctor thinks your loved one's chances for surviving the hospitalization are? [answered on a 5-item Likert scale]

Standardized assessments are then administered:

Wake Forest Physician Trust Scale

Demographic questions [education level, ethnicity, race, sex, ZIP code]

Participants then view 3 of 16 hypothetical, previously-validated text-based prognostic statements and are then asked to answer their prognostic interpretation on a 0-100% scale.

Two more standardized assessments are then administered:

Short Test of Functional Health Literacy in Adults

Rasch-based numeracy assessment

Finally, the survey ends. An option appears for two further optional questions which the participant may answer if they choose to. Completion of these two questions is not considered criteria for study completion:

Optional Free text box allowing the participant to write any comments they have about how doctors and family members of sick patients communicate.

Optional area to enter name, telephone, and or email to be contacted about future studies.

8.2 SAFETY ASSESSMENTS

N/A

8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS

N/A

8.4 UNANTICIPATED PROBLEMS

8.4.1 DEFINITION OF UNANTICIPATED PROBLEMS

This protocol uses the definition of Unanticipated Problems as defined by the Office for Human Research Protections (OHRP). OHRP considers unanticipated problems involving risks to participants or others to include, in general, any incident, experience, or outcome that meets **all** of the following criteria:

- Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol-related documents, such as the Institutional Review Board (IRB)-approved research protocol and informed consent document; and (b) the characteristics of the participant population being studied;
- Related or possibly related to participation in the research ("possibly related" means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and
- Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

390

391

8.4.2 UNANTICIPATED PROBLEMS REPORTING

392

The investigator will report unanticipated problems (UPs) to the reviewing Institutional Review Board (IRB) and to the lead principal investigator (PI). The UP report will include the following information:

393

394

- Protocol identifying information: protocol title and number, PI's name, and the IRB project number

395

- A detailed description of the event, incident, experience, or outcome

396

- An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP

397

- A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP

398

399

To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:

400

- UPs that are serious adverse events (SAEs) will be reported to the IRB within 7 business days of the investigator becoming aware of the event

401

402

- Any other UP will be reported to the IRB within 7 business days of the investigator becoming aware of the problem

403

- All UPs should be reported to appropriate institutional officials (as required by an institution's written reporting procedures), the supporting agency head (or designee), and the Office for Human Research Protections (OHRP) within 7 business days of the IRB's receipt of the report of the problem from the investigator

404

405

406

8.4.3 REPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS

407

Our trial protocol does not include collection of personally identifiable information, except for an optional section in which the participant can leave an email address or phone number to be contacted about future studies. If necessary to report unanticipated problems to participants we can report to only those who have optionally provided their contact information.

408

409

410

411

412

9 STATISTICAL CONSIDERATIONS

9.1 STATISTICAL HYPOTHESES

- Primary Efficacy Endpoint(s):

We hypothesize that participants will perceive intensivists to be less optimistic when randomized to view a direct answer to their question about prognosis.

- Secondary Efficacy Endpoint(s):

We hypothesize that participants will be less optimistic when they are randomized to view a direct answer to their question about prognosis.

We hypothesize that differences in belief about prognosis (defined as the difference between the proxy's prognostic estimate and the intensivist's perceived estimate) will be unaffected by intensivist communication style.

9.2 SAMPLE SIZE DETERMINATION

Based on surrogate decision makers' interpretations of prognostic information in previous research we estimated that enrolling 75 participants in each arm of the trial would provide power of 0.9 to detect at least an 8 point difference in the mean interpretation of intensivist statements assuming a 2-sided α of 0.05, and an estimated standard deviation of 15.

9.3 POPULATIONS FOR ANALYSES

The per-protocol population will be analyzed. Participants who did not complete the trial will not be analyzed.

9.4 STATISTICAL ANALYSES

9.4.1 GENERAL APPROACH

Descriptive statistics and data visualizations will be used to summarize primary and secondary endpoints, baseline descriptive statistics, and exploratory analyses as described below. Generalized linear regression will be used to estimate the effect of intensivist communication style on primary and secondary outcomes. All analyses will assume a 2-sided alpha of 0.05.

9.4.2 ANALYSIS OF THE PRIMARY ENDPOINT(S)

Multivariable linear regression will be used to estimate the effect of communication pattern (i.e. which video the participant is randomized to view) on perception of the intensivist's prognostic estimate. The direct communication pattern will be treated as the comparator (control group) in all models. All models will be adjusted for the following variables which are hypothesized to confound the relationship between physician communication style and proxy perception of the intensivist's prognostic estimate: 1) the relationship of the participant to their loved one, 2) whether the participant's loved one has previously been mechanically ventilated, 3) education level, 4) numeracy score, 5) trust in physicians score, and 6) health literacy score. Residual plots will be reviewed to evaluate model assumptions. Unadjusted models will also be reported.

9.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S)

Multivariable linear regression will be used to estimate the effect of communication pattern (i.e. which video the participant is randomized to view) on the participant's prognostic estimate and participant difference in belief. The direct communication pattern will be treated as the comparator (control group) in all models. All models will be adjusted for the following variables which are hypothesized to confound the relationship between physician communication style and participant's prognostic estimate and difference in belief: 1) the relationship of the participant to their loved one, 2) whether the participant's loved one has previously been mechanically ventilated, 3) education level, 4) numeracy score, 5) trust in physicians score, and 6) health literacy score. Residual plots will be reviewed to evaluate model assumptions. Unadjusted models will also be reported.

9.4.4 SAFETY ANALYSES

N/A

9.4.5 BASELINE DESCRIPTIVE STATISTICS

Descriptive statistics, either median value with interquartile range or counts and percentages, will be reported for demographic questions as well as participant relationship to the patient, prior experience advocating for someone receiving mechanical ventilation, numeracy score, Wake Forest physician trust scale, and health literacy score.

9.4.6 PLANNED INTERIM ANALYSES

N/A

9.4.7 SUB-GROUP ANALYSES

No specific sub-group analyses are planned.

9.4.8 TABULATION OF INDIVIDUAL PARTICIPANT DATA

N/A

9.4.9 EXPLORATORY ANALYSES

Participants who selected "Confident" or "Very confident" on the 5-point Likert scale are analyzed as being confident with a sensitivity analysis performed to ensure estimates are robust to the threshold chosen for confidence (e.g. including "neutral" as a confident response). The difference in proportion of confident participants is estimated using the sample proportions in each trial arm compared to the control group. The null hypothesis of no difference is tested using the Fisher exact test.

479
480

10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS

10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS

10.1.1.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS

The following language will be presented at the beginning of the online trial:

"You have been selected as a potential participant in a survey about how doctors communicate. This survey is anonymous and no identifying information will be collected. There are no right or wrong answers. The survey should take about 15 minutes to complete and will involve watching a short video clip of a doctor answering a question. If you are upset by the video or survey you can stop at any time. If you take part in this study, you may help others in the future by helping doctors and family members of patients work together in healthcare. Selected information from this survey might be made available for other researchers to work with through a publicly-available database, but no identifying information will be collected by this survey or uploaded to this database. If you have questions about this survey please contact the study team representative Ian Oppenheim at ian@jhmi.edu or the principal investigator Alison Turnbull at turnbull@jhmi.edu. Clicking "I Agree" below will begin the survey and serve as your consent to participate. If you do not agree, please close this web page."

10.1.2 STUDY DISCONTINUATION AND CLOSURE

This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Circumstances that may warrant termination or suspension include, but are not limited to:

- Determination of unexpected, significant, or unacceptable risk to participants
- Data that are not sufficiently complete and/or evaluable

10.1.3 CONFIDENTIALITY AND PRIVACY

Participant confidentiality and privacy is strictly held in trust by the participating investigators, their staff, the safety and oversight monitor(s), and the sponsor(s) and funding agency. This confidentiality is extended to the data being collected as part of this study. Data that could be used to identify a specific study participant will be held in strict confidence within the research team. No personally-identifiable information from the study will be released to any unauthorized third party without prior written approval of the sponsor/funding agency.

The study monitor, other authorized representatives of the sponsor, representatives of the Institutional Review Board (IRB), or regulatory agencies may inspect all documents and records required to be maintained by the investigator. The clinical study site will permit access to such records. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by the reviewing IRB, Institutional policies, or sponsor requirements.

15 January 2020

Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the Johns Hopkins University. This will not include the participant's contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by study site research staff will be secured and password protected. At the end of the study, all study databases will be de-identified and archived at the Johns Hopkins University.

The PI will ensure all mechanisms used to share data will include proper plans and safeguards for the protection of privacy, confidentiality, and security for data dissemination and reuse (e.g., all data will be thoroughly de-identified and will not be traceable to a specific study participant). Plans for archiving and long-term preservation of the data will be implemented, as appropriate.

10.1.4 FUTURE USE OF STORED SPECIMENS AND DATA

Data collected for this study will be analyzed and stored at the Johns Hopkins University. After the study is completed, the de-identified, archived data will be transmitted to and stored at the Johns Hopkins University Data Archive. When the study is completed, access to archived data will be provided through Johns Hopkins University.

10.1.6 SAFETY OVERSIGHT

N/A

10.1.7 CLINICAL MONITORING

N/A

10.1.8 QUALITY ASSURANCE AND QUALITY CONTROL

N/A

10.1.9 DATA HANDLING AND RECORD KEEPING

10.1.9.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES

Data collection will be the responsibility of the clinical trial staff at the site under the supervision of the site investigator. The investigator will be responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.

10.1.9.2 STUDY RECORDS RETENTION

Study documents will be retained for a minimum of 2 years after formal discontinuation of the study. It is the responsibility of the investigator to determine when these documents no longer need to be retained.

10.1.10 PROTOCOL DEVIATIONS

This protocol defines a protocol deviation as any noncompliance with the clinical trial protocol. The noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions will be developed by the site and implemented promptly.

10.1.11 PUBLICATION AND DATA SHARING POLICY

This study will be conducted in accordance with the following publication and data sharing policies and regulations: National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication.

This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer-reviewed journals. Considerations for ensuring confidentiality of these shared data are described in Section 10.1.3.

10.1.12 CONFLICT OF INTEREST POLICY

The independence of this study from any actual or perceived influence, such as by the pharmaceutical industry, is critical. Therefore any actual conflict of interest of persons who have a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be required to have such conflicts managed in a way that is appropriate to their participation in the design and conduct of this trial.

10.2 ADDITIONAL CONSIDERATIONS

10.3 ABBREVIATIONS AND SPECIAL TERMS

10.4 PROTOCOL AMENDMENT HISTORY

| Version | Date | Description of Change | Brief Rationale |
|---------|------|-----------------------|-----------------|
| | | | |
| | | | |
| | | | |

11 REFERENCES

REFERENCES

1. Fischer S, Min SJ, Cervantes L, Kutner J, Where do you want to spend your last days of life? Low concordance between preferred and actual site of death among hospitalized adults., *J Hosp Med.* 2013 Apr;8(4):178-83

Pmid:23440934
2. Barnato AE, Herndon MB, Anthony DL, Gallagher PM, Skinner JS, Bynum JP, Fisher ES, Are regional variations in end-of-life care intensity explained by patient preferences?: A Study of the US Medicare Population., *Med Care.* 2007 May;45(5):386-93

Pmid:17446824
3. Auriemma CL, Nguyen CA, Bronheim R, Kent S, Nadiger S, Pardo D, Halpern SD, Stability of end-of-life preferences: a systematic review of the evidence., *JAMA Intern Med.* 2014 Jul;174(7):1085-92

Pmid:24861560
4. Needham DM, Bronskill SE, Calinawan JR, Sibbald WJ, Pronovost PJ, Laupacis A, Projected incidence of mechanical ventilation in Ontario to 2026: Preparing for the aging baby boomers., *Crit Care Med.* 2005 Mar;33(3):574-9

Pmid:15753749
5. Angus DC, Barnato AE, Linde-Zwirble WT, Weissfeld LA, Watson RS, Rickert T, Rubenfeld GD, Robert Wood Johnson Foundation ICU End-Of-Life Peer Group., Use of intensive care at the end of life in the United States: an epidemiologic study., *Crit Care Med.* 2004 Mar;32(3):638-43

Pmid:15090940
6. Teno JM, Gozalo P, Trivedi AN, Bunker J, Lima J, Ogarek J, Mor V, Site of Death, Place of Care, and Health Care Transitions Among US Medicare Beneficiaries, 2000-2015., *JAMA.* 2018 Jul 17;320(3):264-271

Pmid:29946682

- 615 7. Teno JM, Gozalo P, Khandelwal N, Curtis JR, Meltzer D, Engelberg R, Mor V, Association of Increasing Use of Mechanical
616 Ventilation Among Nursing Home Residents With Advanced Dementia and Intensive Care Unit Beds., JAMA Intern Med.
617 2016 Dec 1;176(12):1809-1816
- 618 Pmid:27723891
- 619
- 620
- 621 8. Wunsch H, Linde-Zwirble WT, Harrison DA, Barnato AE, Rowan KM, Angus DC, Use of intensive care services during terminal
622 hospitalizations in England and the United States., Am J Respir Crit Care Med. 2009 Nov 1;180(9):875-80
- 623 Pmid:19713448
- 624
- 625
- 626 9. Bekelman JE, Halpern SD, Blankart CR, Bynum JP, Cohen J, Fowler R, Kaasa S, Kwietniewski L, Melberg HO, Onwuteaka-
627 Philipsen B, Oosterveld-Vlug M, Pring A, Schreyögg J, Ulrich CM, Verne J, Wunsch H, Emanuel EJ, International Consortium
628 for End-of-Life Research (ICELR)., Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for
629 Patients Dying With Cancer in 7 Developed Countries., JAMA. 2016 Jan 19;315(3):272-83
- 630 Pmid:26784775
- 631
- 632
- 633 10. Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG, Place of death: correlations with quality of life of
634 patients with cancer and predictors of bereaved caregivers' mental health., J Clin Oncol. 2010 Oct 10;28(29):4457-64
- 635 Pmid:20837950
- 636
- 637
- 638 11. Halpern SD, Becker D, Curtis JR, Fowler R, Hyzy R, Kaplan LJ, Rawat N, Sessler CN, Wunsch H, Kahn JM, Choosing Wisely
639 Taskforce., American Thoracic Society., American Association of Critical-Care Nurses., Society of Critical Care Medicine., An
640 official American Thoracic Society/American Association of Critical-Care Nurses/American College of Chest
641 Physicians/Society of Critical Care Medicine policy statement: the Choosing Wisely® Top 5 list in Critical Care Medicine., Am
642 J Respir Crit Care Med. 2014 Oct 1;190(7):818-26
- 643 Pmid:25271745
- 644
- 645
- 646 12. Silveira MJ, Kim SY, Langa KM, Advance directives and outcomes of surrogate decision making before death., N Engl J Med.
647 2010 Apr 1;362(13):1211-8
- 648 Pmid:20357283
- 649
- 650

- 651 13. Turnbull AE, Hartog CS, Goal-concordant care in the ICU: a conceptual framework for future research., Intensive Care Med.
652 2017 Dec;43(12):1847-1849
- 653
654 Pmid:28656453
655
- 656 14. Committee on Approaching Death: Addressing Key End of Life Issues, Institute of Medicine, . 2015 Mar 19;
- 657
658 Pmid:25927121
659
- 660 15. Lee Char SJ, Evans LR, Malvar GL, White DB, A randomized trial of two methods to disclose prognosis to surrogate decision
661 makers in intensive care units., Am J Respir Crit Care Med. 2010 Oct 1;182(7):905-9
- 662
663 Pmid:20538959
664
- 665 16. Barnato AE, Arnold RM, The effect of emotion and physician communication behaviors on surrogates' life-sustaining
666 treatment decisions: a randomized simulation experiment., Crit Care Med. 2013 Jul;41(7):1686-91
- 667
668 Pmid:23660727
669
- 670 17. White DB, Ernecoff N, Buddadhumaruk P, Hong S, Weissfeld L, Curtis JR, Luce JM, Lo B, Prevalence of and Factors Related to
671 Discordance About Prognosis Between Physicians and Surrogate Decision Makers of Critically Ill Patients., JAMA. 2016 May
672 17;315(19):2086-94
- 673
674 Pmid:27187301
675
- 676 18. Fried TR, Bradley EH, O'Leary J, Prognosis communication in serious illness: perceptions of older patients, caregivers, and
677 clinicians., J Am Geriatr Soc. 2003 Oct;51(10):1398-403
- 678
679 Pmid:14511159
680
- 681 19. Chiarchiaro J, Buddadhumaruk P, Arnold RM, White DB, Quality of communication in the ICU and surrogate's understanding
682 of prognosis., Crit Care Med. 2015 Mar;43(3):542-8
- 683
684 Pmid:25687030
685

686 20. Boyd EA, Lo B, Evans LR, Malvar G, Apatira L, Luce JM, White DB, "It's not just what the doctor tells me:" factors that
687 influence surrogate decision-makers' perceptions of prognosis., Crit Care Med. 2010 May;38(5):1270-5

688
689 Pmid:20228686
690

691 21. Verceles AC, Corwin DS, Afshar M, Friedman EB, McCurdy MT, Shanholtz C, Oakjones K, Zubrow MT, Titus J, Netzer G, Half
692 of the family members of critically ill patients experience excessive daytime sleepiness., Intensive Care Med. 2014
693 Aug;40(8):1124-31

694
695 Pmid:24898893
696

697 22. Glick DR, Motta M, Wiegand DL, Range P, Reed RM, Verceles AC, Shah NG, Netzer G, Anticipatory grief and impaired
698 problem solving among surrogate decision makers of critically ill patients: A cross-sectional study., Intensive Crit Care Nurs.
699 2018 Dec;49:1-5

700
701 Pmid:30057337
702

703 23. Pochard F, Azoulay E, Chevret S, Lemaire F, Hubert P, Canoui P, Grassin M, Zittoun R, le Gall JR, Dhainaut JF, Schlemmer B,
704 French FAMIREA Group., Symptoms of anxiety and depression in family members of intensive care unit patients: ethical
705 hypothesis regarding decision-making capacity., Crit Care Med. 2001 Oct;29(10):1893-7

706
707 Pmid:11588447
708

709 24. Azoulay E, Pochard F, Kentish-Barnes N, Chevret S, Aboab J, Adrie C, Annane D, Bleichner G, Bollaert PE, Darmon M, Fassier
710 T, Galliot R, Garrouste-Orgeas M, Goulenok C, Goldgran-Toledano D, Hayon J, Jourdain M, Kaidomar M, Laplace C, Larché J,
711 Liotier J, Papazian L, Poisson C, Reignier J, Saidi F, Schlemmer B, FAMIREA Study Group., Risk of post-traumatic stress
712 symptoms in family members of intensive care unit patients., Am J Respir Crit Care Med. 2005 May 1;171(9):987-94

713
714 Pmid:15665319
715

716 25. Paulus MP, Yu AJ, Emotion and decision-making: affect-driven belief systems in anxiety and depression., Trends Cogn Sci.
717 2012 Sep;16(9):476-83

718
719 Pmid:22898207
720

721 26. Turnbull AE, Hashem MD, Rabiee A, To A, Chessare CM, Needham DM, Evaluation of a strategy for enrolling the families of
722 critically ill patients in research using limited human resources., PLoS One. 2017;12(5):e0177741

723
724
725

726
727
728

729
730
731

732
733
734

735
736
737

738
739

740
741
742

743
744
745

746
747
748

749
750
751

752
753
754

755
756

757
758
759

Pmid:28542632

27. Schwarzkopf D, Behrend S, Skupin H, Westermann I, Riedemann NC, Pfeifer R, Günther A, Witte OW, Reinhart K, Hartog CS, Family satisfaction in the intensive care unit: a quantitative and qualitative analysis., Intensive Care Med. 2013 Jun;39(6):1071-9

Pmid:23417207

28. Bein T, Hackner K, Zou T, Schultes S, Bösch T, Schlitt HJ, Graf BM, Olden M, Leitzmann M, Socioeconomic status, severity of disease and level of family members' care in adult surgical intensive care patients: the prospective ECSSTASI study., Intensive Care Med. 2012 Apr;38(4):612-9

Pmid:22273749

29. Bahadori K, FitzGerald JM, Risk factors of hospitalization and readmission of patients with COPD exacerbation--systematic review., Int J Chron Obstruct Pulmon Dis. 2007;2(3):241-51

Pmid:18229562

30. Quintana JM, Esteban C, Unzurrunzaga A, Garcia-Gutierrez S, Gonzalez N, Lafuente I, Bare M, de Larrea NF, Vidal S, IRYSS-COPD Group., Prognostic severity scores for patients with COPD exacerbations attending emergency departments., Int J Tuberc Lung Dis. 2014 Dec;18(12):1415-20

Pmid:25517805

31. Turnbull AE, Krall JR, Ruhl AP, Curtis JR, Halpern SD, Lau BM, Needham DM, A scenario-based, randomized trial of patient values and functional prognosis on intensivist intent to discuss withdrawing life support., Crit Care Med. 2014 Jun;42(6):1455-62

Pmid:24584065

32. Turnbull AE, Hayes MM, Brower RG, Colantuoni E, Basyal PS, White DB, Curtis JR, Needham DM, Effect of Documenting Prognosis on the Information Provided to ICU Proxies: A Randomized Trial., Crit Care Med. 2019 Jun;47(6):757-764

Pmid:30882479

- 760 33. Vasher ST, Zaeh SE, Eakin MN, Turnbull AE, Responses to a Daughter's Question about Prognosis When the Patient Is
761 Expected to Die: A Qualitative Analysis., Ann Am Thorac Soc. 2019 Dec;16(12):1595-1598

762
763 [Pmid:31419913](#)
764